Jacobio Pharma Announces 2024 Annual Results

Jacobio Pharma Announces 2024 Annual Results

BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320...

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

BEIJING, SHANGHAI and BOSTON, Jan. 7, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed...

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263...

menu
menu